LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Early this month, the Humira maker said that the non-cash charge reflected two failed mid-stage trials designed to evaluate Cerevel Therapeutics' lead drug, emraclidine, in schizophrenia.

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

That is why the market saw AbbVie make a number of acquisitions to expand its pipeline and offset that loss. In 2024, the ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro and Zepbound.